[go: up one dir, main page]

WO2012104874A3 - Aqueous concentrated formulation of linezolid - Google Patents

Aqueous concentrated formulation of linezolid Download PDF

Info

Publication number
WO2012104874A3
WO2012104874A3 PCT/IN2012/000080 IN2012000080W WO2012104874A3 WO 2012104874 A3 WO2012104874 A3 WO 2012104874A3 IN 2012000080 W IN2012000080 W IN 2012000080W WO 2012104874 A3 WO2012104874 A3 WO 2012104874A3
Authority
WO
WIPO (PCT)
Prior art keywords
linezolid
aqueous concentrated
concentrated formulation
formulation
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2012/000080
Other languages
French (fr)
Other versions
WO2012104874A2 (en
Inventor
Suraj VELHAL
Harish CHINNARI
Subhash Gore
Manoj Pananchukunnath
Rajesh Gupta
Indu Bhushan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Laboratories Ltd
Original Assignee
Mylan Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Laboratories Ltd filed Critical Mylan Laboratories Ltd
Publication of WO2012104874A2 publication Critical patent/WO2012104874A2/en
Publication of WO2012104874A3 publication Critical patent/WO2012104874A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed is the aqueous concentrated formulation of linezolid, more particularly, the aqueous concentrated formulation of linezolid comprising at least one solubilizer, wherein the formulation is preferably administered intravenously.
PCT/IN2012/000080 2011-02-02 2012-02-02 Aqueous concentrated formulation of linezolid Ceased WO2012104874A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN307CH2011 2011-02-02
IN307/CHE/2011 2011-02-02

Publications (2)

Publication Number Publication Date
WO2012104874A2 WO2012104874A2 (en) 2012-08-09
WO2012104874A3 true WO2012104874A3 (en) 2012-11-01

Family

ID=46603173

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2012/000080 Ceased WO2012104874A2 (en) 2011-02-02 2012-02-02 Aqueous concentrated formulation of linezolid

Country Status (1)

Country Link
WO (1) WO2012104874A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104173949B (en) * 2014-09-12 2017-04-05 大理药业股份有限公司 A kind of XINGNAOJING ZHUSHEYE and preparation method thereof
CN106491528B (en) * 2016-12-02 2019-09-24 江苏豪森药业集团有限公司 Linezolid Injection and preparation method thereof
CN111920772A (en) * 2020-09-04 2020-11-13 浙江普利药业有限公司 Linezolid dry suspension and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1130379A (en) * 1993-09-09 1996-09-04 厄普约翰公司 Substituted oxazine and thiazine oxazolidinone antimicrobials
WO2002030395A1 (en) * 2000-10-10 2002-04-18 Pharmacia & Upjohn Company Topical antibiotic composition for treatment of eye infection
CN1713924A (en) * 2000-08-22 2005-12-28 法马西亚公司 Oxazolidinone antibacterial drug solution composition with increased drug content
CN101948442A (en) * 2009-07-10 2011-01-19 符健 Preparation method of linezolid and preparation thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1130379A (en) * 1993-09-09 1996-09-04 厄普约翰公司 Substituted oxazine and thiazine oxazolidinone antimicrobials
CN1713924A (en) * 2000-08-22 2005-12-28 法马西亚公司 Oxazolidinone antibacterial drug solution composition with increased drug content
WO2002030395A1 (en) * 2000-10-10 2002-04-18 Pharmacia & Upjohn Company Topical antibiotic composition for treatment of eye infection
CN101948442A (en) * 2009-07-10 2011-01-19 符健 Preparation method of linezolid and preparation thereof

Also Published As

Publication number Publication date
WO2012104874A2 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
MX2015008627A (en) Boronic acid derivatives and therapeutic uses thereof.
MX2016015093A (en) Boronic acid derivatives and therapeutic uses thereof.
MX361499B (en) Deuterated baricitinib.
IT1404931B1 (en) OPHTHALMIC COMPOSITIONS FOR THE ADMINISTRATION OF LIPO-SOLUBLE ACTIVE PRINCIPLES.
EP3040072A4 (en) Pharmaceutical composition having pyrimidine compound as active ingredient
NI201500135A (en) PHARMACEUTICAL COMPOSITION OF S-KETAMINE HYDROCHLORIDE
EP4309735A3 (en) Pharmaceutical composition of s-ketamine hydrochloride
TW201144301A (en) Processes for preparing linezolid
PH12015500900A1 (en) A stabilized pemetrexed formulation
WO2013003669A3 (en) Compositions, methods of use, and methods of treatment
CA2873723A1 (en) Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
TWD161614S (en) Bottle
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
WO2012162414A3 (en) Shirt collar stabilizer
WO2014160281A3 (en) Method of enhancing delivery of therapeutic compounds to the eye
UA115357C2 (en) Pyridin-4-yl derivatives
WO2011079193A3 (en) Preparation of bendamustine and its salts
CL2014003123A1 (en) 5-amino [1,4], thiazines as bace1 inhibitors; use of the compound against Alzheimer's disease.
WO2015173427A3 (en) Rapid-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
HK1212978A1 (en) Novel derivatives of sinapinic acid
WO2014155389A3 (en) Process for preparation of ticagrelor
WO2012104874A3 (en) Aqueous concentrated formulation of linezolid
WO2012154879A3 (en) Autophagy inhibitors
EP2864328B8 (en) Pharmaceutically active compounds
EP3064501A4 (en) 2-methylsulphanyl-6-nitro-7-oxo-1, 2, 4-triazolo [5, 1-c][1, 2, 4]triazinide l-arginine dihydrate active toward west nile virus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12741785

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12741785

Country of ref document: EP

Kind code of ref document: A2